Akero Therapeutics Inc
AKRO54.650USD
0.0000.00%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
4.38BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Akero Therapeutics Inc Unternehmen
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Akero Therapeutics Inc Informationen
BörsenkürzelAKRO
Name des UnternehmensAkero Therapeutics Inc
IPO-datumJun 20, 2019
CEOCheng (Andrew)
Anzahl der mitarbeiter63
WertpapierartOrdinary Share
GeschäftsjahresendeJun 20
Addresse601 Gateway Boulevard, Suite 350
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16504876488
Websitehttps://akerotx.com/
BörsenkürzelAKRO
IPO-datumJun 20, 2019
CEOCheng (Andrew)
Führungskräfte von Akero Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-89277.00%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+8266.00%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-200189.00%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Pritchett Henderson
Ms. Jane Pritchett Henderson
Independent Director
Independent Director
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-89277.00%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+8266.00%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-200189.00%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
7.63%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.08%
Wellington Management Company, LLP
5.16%
Andere
67.51%
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
7.63%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.08%
Wellington Management Company, LLP
5.16%
Andere
67.51%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
45.16%
Investment Advisor
23.71%
Hedge Fund
18.04%
Private Equity
9.73%
Research Firm
2.95%
Venture Capital
2.56%
Individual Investor
1.08%
Foundation
0.40%
Bank and Trust
0.24%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
504
92.63M
123.44%
-26.38K
2025Q3
532
92.72M
128.44%
-619.25K
2025Q2
513
93.19M
122.60%
+5.80M
2025Q1
481
87.41M
107.62%
+1.72M
2024Q4
438
74.28M
124.07%
+570.22K
2024Q3
432
73.67M
126.17%
-695.38K
2024Q2
416
72.42M
128.65%
-3.01M
2024Q1
408
73.91M
107.89%
+1.88M
2023Q4
389
59.72M
117.03%
+1.94M
2023Q3
376
57.78M
113.32%
+701.00K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Janus Henderson Investors
6.28M
7.63%
-458.25K
-6.80%
Sep 30, 2025
General Atlantic LLC
5.73M
6.97%
--
--
Sep 30, 2025
RTW Investments L.P.
5.48M
6.65%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.01M
6.08%
-54.14K
-1.07%
Sep 30, 2025
Wellington Management Company, LLP
4.25M
5.16%
+841.91K
+24.69%
Sep 30, 2025
Deep Track Capital LP
4.00M
4.86%
+958.38K
+31.50%
Sep 30, 2025
Avoro Capital Advisors LLC
3.96M
4.8%
+455.56K
+13.02%
Sep 30, 2025
T. Rowe Price Associates, Inc.
3.72M
4.52%
-702.58K
-15.89%
Sep 30, 2025
State Street Investment Management (US)
3.41M
4.15%
+668.74K
+24.36%
Sep 30, 2025
Bellevue Asset Management AG
2.39M
2.9%
+404.04K
+20.35%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Simplify Propel Opportunities ETF
11.66%
ProShares Merger ETF
2.71%
State Street SPDR S&P Biotech ETF
1.78%
ALPS Medical Breakthroughs ETF
1.75%
AltShares Merger Arbitrage ETF
1.63%
Direxion Daily S&P Biotech Bull 3X Shares
1.1%
ProShares Ultra Nasdaq Biotechnology
0.43%
Invesco Nasdaq Biotechnology ETF
0.42%
iShares Biotechnology ETF
0.34%
Pacer WealthShield ETF
0.28%
Mehr Anzeigen
Simplify Propel Opportunities ETF
Anteil11.66%
ProShares Merger ETF
Anteil2.71%
State Street SPDR S&P Biotech ETF
Anteil1.78%
ALPS Medical Breakthroughs ETF
Anteil1.75%
AltShares Merger Arbitrage ETF
Anteil1.63%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil1.1%
ProShares Ultra Nasdaq Biotechnology
Anteil0.43%
Invesco Nasdaq Biotechnology ETF
Anteil0.42%
iShares Biotechnology ETF
Anteil0.34%
Pacer WealthShield ETF
Anteil0.28%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
